Added to YB: 2024-09-16
Pitch date: 2024-06-30
AVIR [bullish]
Atea Pharmaceuticals, Inc.
-4.26%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
Market Cap
$266.1M
Pitch Price
$3.29
Price Target
N/A
Dividend
N/A
EV/EBITDA
1.73
P/E
-1.52
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Show full summary:
Harris Associates International Small Cap Strategy Portfolio Holding: Atea Pharmaceuticals, Inc.
AVIR: Nordic IT reseller beats Q1 expectations. Hardware rev down, software/services up. Margins exceeded forecasts. Strong leadership & market position in growing sector. Attractive upside potential despite hardware decline.
Read full article (1 min)